CSL Behring Discontinues Monoclate-P® Production

March 6, 2018

CSL Behring has made the decision to discontinue Monoclate-P®, antihemophilic factor (human), factor VIII. According to the manufacturer, "as hemophilia A treatment has advanced, and patients have transitioned from plasma-derived to recombinant and longer-acting therapies, it has been increasingly difficult to sustain the production and distribution of Monoclate-P."

CSL estimates that supply will be available through December 2018, which gives you time to consider different treatment options for your patients.

FFF is Here to Help

Due to this recent information regarding Monoclate-P, we recognize you may need to seek out and order an alternative coagulation product. FFF is ready to help and have the following options available to meet your factor VIII patient needs.

Product

Manufacturer

Factor VIII (Recombinant)

ADVATE®

Shire

Helixate® FS

CSL Behring

Kogenate® FS

Bayer

KOVALTRY®

Bayer

 Novoeight®

Novo Nordisk

NUWIQ®

Octapharma

RECOMBINATE™

Shire

XYNTHA®

Pfizer

XYNTHA® SOLOFUSE®

Pfizer

Factor VIII (Recombinant), Long-Acting

 ADYNOVATE®

Shire

AFSTYLA®

CSL Behring

ELOCTATE®

Bioverativ

Factor VIII (Human)

Hemofil® M

Shire

Koate®-DVI

Kedrion

Factor VIII/von Willebrand Factor Complex (Human)

Alphanate®

Grifols

Humate-P®

CSL Behring

WILATE®

Octapharma

If you have any questions or need assistance,
please call your FFF Sales Representative or Wow! Customer Care at (800) 843-7477.